Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, net loss was USD 0.379431 million compared to USD 1.69 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.23 a year ago. Diluted loss per share from continuing operations was USD 0.05 compared to USD 0.23 a year ago.